Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRASTEK (phleum pratense pollen) is a standardized allergenic extract administered as a sublingual tablet for the treatment of grass pollen-induced allergic rhinitis, with or without conjunctivitis. Developed by ALK-Abello in partnership with Merck, it contains a standardized extract of Timothy grass (*Phleum pratense*) pollen. The drug functions as an allergen immunotherapy, which aims to induce immunological tolerance by repeatedly exposing the patient to the allergen. This process modulates the IgE-mediated immune response, shifting the balance toward a T-regulatory cell response and increasing allergen-specific IgG4 antibodies. It is indicated for patients aged 5 to 65 years who have a confirmed sensitivity to Timothy grass or cross-reactive grass pollens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phleum pratense pollen.